Nature Reviews Drug Discovery - AOP - nature.com science feeds http://www.nature.com/nrd/current_issue/ Nature Publishing Group en © Nature Publishing Group Nature Reviews Drug Discovery 1474-1776 © Nature Publishing Group permissions@nature.com Nature Reviews Drug Discovery http://www.nature.com/includes/rj_globnavimages/nrd_logo.gif http://www.nature.com/nrd/ Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells http://feeds.nature.com/~r/nrd/rss/aop/~3/WyepK1ybuhM/nrd3031 Many inhibitors of histone deacetylases (HDACs) are in trials in patients with cancer, but a subset of HDAC inhibitors also have anti-inflammatory or immunosuppressive effects that may be of therapeutic benefit in autoimmune diseases or post-transplantation. Hancock and colleagues describe these effects, highlighting the importance of the ability of some HDAC inhibitors to enhance the production and suppressive functions of FOXP3+ regulatory T cells, and discuss the potential to develop class- or subclass-specific HDAC inhibitors as novel immunotherapies. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells

Nature Reviews Drug Discovery. doi:10.1038/nrd3031

Authors: Liqing Wang, Edwin F. de Zoeten, Mark I. Greene & Wayne W. Hancock

]]> Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells Liqing Wang Edwin F. de Zoeten Mark I. Greene Wayne W. Hancock doi:10.1038/nrd3031 Nature Reviews Drug Discovery 2009-10-26 Nature Reviews Drug Discovery 2009-10-26 10.1038/nrd3031 http://dx.doi.org/10.1038/nrd3031 Review http://dx.doi.org/10.1038/nrd3031 The future of drug development: advancing clinical trial design http://feeds.nature.com/~r/nrd/rss/aop/~3/TeKQ5TNO84w/nrd3025 Orloff and colleagues describe how moving from the traditional approach to clinical trials based on sequential, distinct phases towards a more integrated strategy that increases flexibility and maximizes the use of accumulated knowledge could have a key role in improving the efficiency and cost-effectiveness of drug development. Using examples in which novel trial designs have been successfully applied, they also illustrate the use of the tools involved, such as Bayesian methodologies, and discuss the advantages and challenges for their more widespread implementation. The future of drug development: advancing clinical trial design

Nature Reviews Drug Discovery. doi:10.1038/nrd3025

Authors: John Orloff, Frank Douglas, Jose Pinheiro, Susan Levinson, Michael Branson, Pravin Chaturvedi, Ene Ette, Paul Gallo, Gigi Hirsch, Cyrus Mehta, Nitin Patel, Sameer Sabir, Stacy Springs, Donald Stanski, Matthias R. Evers, Edd Fleming, Navjot Singh, Tony Tramontin & Howard Golub

]]> The future of drug development: advancing clinical trial design John Orloff Frank Douglas Jose Pinheiro Susan Levinson Michael Branson Pravin Chaturvedi Ene Ette Paul Gallo Gigi Hirsch Cyrus Mehta Nitin Patel Sameer Sabir Stacy Springs Donald Stanski Matthias R. Evers Edd Fleming Navjot Singh Tony Tramontin Howard Golub doi:10.1038/nrd3025 Nature Reviews Drug Discovery 2009-10-09 Nature Reviews Drug Discovery 2009-10-09 10.1038/nrd3025 http://dx.doi.org/10.1038/nrd3025 Perspectives http://dx.doi.org/10.1038/nrd3025